Taysha Gene Therapies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Taysha Gene Therapies's earnings have been declining at an average annual rate of -15.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 104.8% per year.
Anahtar bilgiler
-15.4%
Kazanç büyüme oranı
13.6%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 104.8% |
| Özkaynak getirisi | -105.0% |
| Net Marj | -888.2% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Oct 14More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Jun 27
Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Jun 20Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07Gelir ve Gider Dağılımı
Taysha Gene Therapies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 13 | -114 | 30 | 60 |
| 31 Mar 24 | 14 | -118 | 28 | 65 |
| 31 Dec 23 | 15 | -112 | 30 | 57 |
| 30 Sep 23 | 14 | -214 | 30 | 54 |
| 30 Jun 23 | 10 | -124 | 33 | 60 |
| 31 Mar 23 | 7 | -133 | 35 | 66 |
| 31 Dec 22 | 3 | -166 | 37 | 91 |
| 30 Sep 22 | 0 | -161 | 42 | 116 |
| 30 Jun 22 | 0 | -186 | 44 | 139 |
| 31 Mar 22 | 0 | -193 | 45 | 146 |
| 31 Dec 21 | 0 | -175 | 41 | 132 |
| 30 Sep 21 | 0 | -142 | 36 | 106 |
| 30 Jun 21 | 0 | -106 | 28 | 78 |
| 31 Mar 21 | 0 | -87 | 19 | 50 |
| 31 Dec 20 | 0 | -60 | 11 | 32 |
Kaliteli Kazançlar: TSHA is currently unprofitable.
Büyüyen Kar Marjı: TSHA is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TSHA is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Büyüme Hızlandırma: Unable to compare TSHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: TSHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: TSHA has a negative Return on Equity (-105.02%), as it is currently unprofitable.